-
公开(公告)号：USRE46757E1
公开(公告)日：2018-03-20
申请号：US14755691
申请日：2015-06-30
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Jagdis Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark Legrand , Katrin Spiegel
IPC: A61K31/5355 , C07D213/26 , A61K31/4965 , A61K31/4453 , C07D241/16 , C07D213/04 , C07D213/61 , C07D413/12 , C07D211/06 , A61K31/497 , C07D213/22 , A61K31/445 , A61K31/444 , A61K31/443 , A61K31/454 , A61K31/44 , A61K31/4439 , A61K31/4418 , A61K31/4545 , A61K31/4412 , A61K31/5377 , A61K45/06 , C07D213/81 , C07D241/28 , C07D241/26 , C07D213/38 , C07D401/12 , C07D401/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04
CPC classification number: A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D213/38 , C07D213/81 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/12
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
Patent Agency Ranking
公开(公告)号：US11911371B2
公开(公告)日：2024-02-27
申请号：US17221555
申请日：2021-04-02
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Jagdis Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark Le Grand , Katrin Spiegel
IPC: A61K31/4439 , A61K31/5377 , A61K45/06 , A61K31/44 , A61K31/4418 , C07D241/28 , C07D213/81 , C07D401/04 , C07D405/12 , C07D413/04 , C07D413/12 , A61K31/443 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , C07D213/38 , C07D401/12 , C07D403/12 , A61K31/4412 , C07D405/04 , C07D241/26
CPC classification number: A61K31/44 , A61K31/443 , A61K31/444 , A61K31/4412 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/497 , A61K31/4965 , A61K31/5377 , A61K45/06 , C07D213/38 , C07D213/81 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/12
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
公开(公告)号：US10183025B2
公开(公告)日：2019-01-22
申请号：US15673155
申请日：2017-08-09
Applicant: Novartis AG
Inventor： David Beattie , Urs Baettig , Darren Mark Le Grand , Andrew Stuart Lister , Jeffrey McKenna , David William Pearce , David Andrew Sandham , Oliver Ross Steward , Christopher Thomson
IPC: A61K31/445 , A61K31/551 , C07D403/12 , C07D401/14 , C07D413/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/5377 , A61K31/5513 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D257/04 , A61K45/06 , A61K31/45 , A61K31/496 , A61K31/504 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D471/08
Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
-
公开(公告)号：US10117858B2
公开(公告)日：2018-11-06
申请号：US15156528
申请日：2016-05-17
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark LeGrand , Katrin Spiegel
IPC: A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4412 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K45/06 , A61K31/4418 , C07D213/81 , C07D241/28 , C07D401/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D213/38 , C07D401/12 , C07D403/12 , C07D405/04 , C07D241/26
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
公开(公告)号：US09763957B2
公开(公告)日：2017-09-19
申请号：US14906161
申请日：2014-07-16
Applicant: Novartis AG
Inventor： David Beattie , Urs Baettig , Darren Mark Legrand , Andrew Stuart Lister , Jeffrey McKenna , David William Pearce , David Andrew Sandham , Oliver Ross Steward , Christopher Thomson
IPC: A61K31/445 , A61K31/551 , C07D403/12 , C07D401/14 , C07D413/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/5377 , A61K31/5513 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D257/04 , A61K45/06 , A61K31/45 , A61K31/496 , A61K31/504 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D471/08
CPC classification number: A61K31/551 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/439 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/504 , A61K31/506 , A61K31/5377 , A61K31/5513 , A61K45/06 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/08 , A61K2300/00
Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
-
公开(公告)号：US09365552B2
公开(公告)日：2016-06-14
申请号：US14521843
申请日：2014-10-23
Applicant: Novartis AG
Inventor： Urs Baettig , Kamlesh Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark Legrand , Katrin Spiegel
IPC: A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K31/4418 , A61K45/06 , C07D405/04 , C07D213/81 , C07D241/28 , C07D401/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D213/38 , C07D401/12 , C07D403/12 , A61K31/4412
CPC classification number: A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D213/38 , C07D213/81 , C07D241/26 , C07D241/28 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D413/04 , C07D413/12
Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
-
-
-
-
-
Search Results
6
records
(took 0.037 seconds)
